patient
past
histori
diffus
prolif
lupu
nephriti
world
health
organ
class
iv
resist
treatment
corticosteroid
cyclophosphamid
mycophenol
mofetil
enrol
approv
studi
autolog
hsct
patient
refractori
system
lupu
erythematosu
http
clinicaltrialsgov
identifi
receiv
condit
regimen
consist
fludarabin
cyclophosphamid
rituximab
receiv
deplet
autolog
hsct
patient
admit
clinic
center
nation
institut
health
week
transplant
dyspnea
cough
see
fig
summari
clinic
cours
comput
tomographi
ct
scan
show
pulmonari
diseas
discharg
day
later
improv
bronchodil
patient
readmit
nation
institut
health
clinic
center
week
transplant
dri
cough
dyspnea
exert
nasal
congest
rhinorrhea
postnas
drip
daughter
son
cold
one
anoth
previou
week
case
influenza
report
school
physic
examin
show
mildli
cushingoid
young
woman
tachypnea
constant
cough
temperatur
blood
pressur
respiratori
rate
puls
pulmonari
examin
show
dissemin
wheez
rhonchi
remaind
examin
unremark
white
blood
cell
count
neutrophil
lymphocyt
hemoglobin
gmdl
platelet
count
creatinin
mgdl
total
protein
gdl
albumin
gdl
arteri
blood
ga
oxygen
show
hypoxemia
mm
hg
mm
hg
ph
ct
scan
lung
perform
time
admiss
show
bilater
pleural
effus
patchi
area
nodular
infiltr
lung
involv
lobe
nasopharyng
wash
grew
influenza
later
shown
oseltamivir
sensit
neg
influenza
b
respiratori
syncyti
viru
rsv
parainfluenza
virus
adenoviru
adv
induc
sputum
show
neutrophil
cocci
pair
cluster
rod
fungal
mycobacteri
cultur
neg
differenti
diagnosi
includ
influenza
infect
lupu
pneumon
begun
oseltamivir
mg
twice
daili
prednison
increas
mg
daili
repeat
ct
scan
day
treatment
show
improv
bronchoalveolar
lavag
bal
fluid
grew
influenza
viru
neg
bacteria
fungi
mycobacteria
pneumocysti
mycoplasma
chlamydia
legionella
cytomegaloviru
herp
simplex
viru
thoracentesi
show
exud
white
blood
neutrophil
lymphocyt
red
blood
cell
albumin
gdl
serum
albumin
gdl
lactic
acid
dehydrogenas
ul
serum
lactic
acid
dehydrogenas
ul
glucos
mgdl
organ
identifi
microscopi
cultur
worsen
pulmonari
infiltr
open
lung
biopsi
perform
day
hospit
right
lung
show
diffus
alveolar
damag
hyalin
membran
fig
stain
fungu
bacilli
pneumocysti
cytomegaloviru
neg
cultur
virus
includ
influenza
neg
immunohistochemistri
lung
tissu
neg
influenza
adv
continu
concern
potenti
lupu
pneumon
base
result
lung
biopsi
dose
steroid
increas
methylprednisolon
mg
daili
oseltamivir
discontinu
day
week
transplant
initi
oxygen
improv
dose
methylprednisolon
decreas
howev
hypoxemia
subsequ
worsen
repeat
nasopharyng
wash
bal
fluid
continu
grow
influenza
oseltamivir
reinstitut
mg
twice
daili
hospit
day
week
transplant
intraven
immun
globulin
administ
steroid
continu
antivir
sensit
test
subsequ
show
high
level
nm
increas
oseltamivir
resist
oseltamivir
discontinu
inhal
zanamivir
begun
count
obtain
week
transplant
normal
rang
patient
discharg
hospit
zanamivir
taper
dose
steroid
week
transplant
steroid
reinstitut
infiltr
worsen
pulmonari
effus
return
improv
pulmonari
statu
steroid
taper
sequenc
influenza
viru
isol
show
arginin
lysin
mutat
neuraminidas
amino
acid
mutat
previous
shown
associ
oseltamivir
resist
diminish
viral
fit
anim
experi
instabl
vitro
patient
readmit
week
later
week
transplant
worsen
pulmonari
infiltr
zanamivir
continu
nasopharyng
wash
continu
grow
influenza
viru
although
bal
fluid
cultur
neg
respiratori
pathogen
includ
influenza
viru
ribavirin
ad
view
increas
pulmonari
infiltr
persist
shed
influenza
viru
nasopharynx
suggest
reduc
sensit
influenza
viru
zanamivir
cyclophosphamid
ad
final
week
life
persist
concern
lupu
pneumon
worsen
pulmonari
statu
taper
dose
corticosteroid
empir
antibacteri
antifung
ad
patient
die
week
transplant
hypotens
cardiac
arrest
autopsi
lung
show
bronchopneumonia
organ
pneumon
diffus
alveolar
damag
bal
fluid
lung
tissu
obtain
autopsi
neg
cultur
influenza
parainfluenza
virus
adv
rsv
bacteria
fungi
mycobacteria
nocardia
immunohistochemistri
lung
tissu
neg
influenza
adv
standard
test
provid
explan
progress
clinic
cours
lead
death
hsct
recipi
employ
degener
oligonucleotid
primer
dop
polymeras
chain
reaction
pcr
assay
detect
potenti
virus
lung
patient
assay
combin
digest
cellular
dna
sampl
enrich
viru
nucleocapsid
perform
degener
pcr
previous
use
identifi
human
metapneumoviru
rna
bal
fluid
obtain
bal
fluid
lung
tissu
autopsi
perform
remov
cellular
dna
sampl
purifi
viral
dna
rna
protect
nucleocapsid
bal
sampl
treat
dnase
sigma
st
loui
missouri
usa
final
concentr
uml
dnase
dnase
digest
stop
ad
edta
final
concentr
mm
viral
capsid
purifi
ultracentrifug
ml
nacl
mm
trishcl
ph
solut
h
g
rotor
beckman
coulter
inc
fullerton
california
usa
pellet
resuspend
rltbuffer
allprep
dnarna
kit
qiagen
valencia
california
usa
mm
dna
rna
isol
accord
manufactur
instruct
dna
elut
elut
buffer
rna
elut
water
rna
revers
transcrib
cdna
cdna
synthesi
carri
use
first
strand
kit
random
hexam
primer
invitrogen
carlsbad
california
usa
accord
manufactur
instruct
nucleic
acid
obtain
prepar
subject
carri
use
u
low
dna
taq
appli
biosystem
foster
citi
california
usa
pcr
buffer
provid
manufactur
dntp
dop
primer
n
repres
equimolar
distribut
dntp
repres
inosin
follow
cycl
condit
use
initi
denatur
min
follow
cycl
min
min
ramp
min
ramp
min
ramp
min
ramp
min
min
cycl
min
min
min
extens
addit
per
cycl
extens
step
final
extens
step
min
condit
modifi
previous
publish
addit
valid
studi
demonstr
provid
increas
sensit
amplif
genom
data
shown
sampl
prepar
electron
microscopi
em
remov
lung
tissu
paraffin
block
incub
overnight
xylen
rehydr
pb
osmium
tetroxid
dehydr
embed
maragla
epoxi
resin
ultrathin
section
nm
prepar
uranyl
acet
lead
citrat
view
em
philip
transmiss
electron
microscop
amsterdam
netherland
viral
respiratori
cultur
influenza
parainfluenza
virus
adv
rsv
perform
use
shell
vial
method
cell
canin
kidney
cell
diagnost
hybrid
athen
ohio
usa
ultra
respiratori
stain
kit
diagnost
hybrid
product
obtain
cdna
dna
extract
bal
fluid
autopsi
analyz
purifi
gel
electrophoresi
visibl
band
fig
purifi
clone
total
sequenc
read
obtain
sequenc
clone
obtain
compar
databas
genbank
use
tblastx
nation
center
biotechnolog
inform
bethesda
maryland
usa
sequenc
repres
human
sequenc
repres
bacteri
yeast
sequenc
show
greatest
homolog
insect
sequenc
bacteri
fungal
sequenc
detect
judg
like
unrel
ill
bacteri
fungal
cultur
autopsi
neg
sequenc
match
human
cov
genotyp
ident
nucleotid
overlap
n
gene
nucleotid
chang
refer
sequenc
access
number
cov
genotyp
sequenc
avail
genbank
sequenc
genom
region
none
nucleotid
chang
found
cov
hsct
recipi
result
obtain
gener
confirm
bal
fluid
autopsi
sampl
independ
cov
pcr
use
primer
publish
elsewher
fig
qualiti
rna
assess
attempt
pcr
amplif
cellular
housekeep
gene
porphobilinogen
deaminas
insuffici
confirm
presenc
cov
revers
transcript
rt
rna
extract
lung
biopsi
obtain
life
em
autopsi
show
particl
diamet
approxim
nm
fig
examin
previous
obtain
biopsi
materi
also
confirm
presenc
particl
fig
diamet
particl
consist
cov
although
low
end
typic
rang
nm
detect
sequenc
human
cov
lung
tissu
bal
fluid
autopsi
hsct
recipi
previous
treat
influenza
viru
infect
resist
oseltamivir
die
pneumonia
addit
viral
particl
consist
cov
detect
em
biopsi
autopsi
lung
tissu
patient
also
intermitt
suspect
lupu
pneumon
case
illustr
difficulti
make
diagnosi
hsct
patient
multipl
possibl
etiolog
lung
diseas
show
valu
unbias
viru
detect
techniqu
expand
differenti
diagnosi
identifi
pathogen
individu
patient
cov
genotyp
viru
sequenc
lung
group
cov
close
relat
human
cov
distinguish
group
cov
sar
cov
distantli
relat
group
cov
known
genotyp
cov
b
c
genotyp
b
preval
c
studi
australia
itali
retrospect
studi
respiratori
specimen
us
describ
similar
preval
rate
studi
suggest
viru
distribut
worldwid
although
report
number
case
remain
limit
four
lower
respiratori
syndrom
potenti
caus
human
cov
describ
pneumonia
acut
tracheobronch
acut
exacerb
chronic
obstruct
pulmonari
diseas
acut
asthma
exacerb
cov
usual
caus
rel
mild
infect
children
character
rhinorrhea
cough
fever
infect
result
bronchiol
pneumonia
occasion
hypoxia
abnorm
chest
describ
cov
also
relat
high
incid
febril
seizur
anoth
studi
impli
cov
could
associ
enter
symptom
pneumonia
relat
cov
infect
occur
mostli
older
peopl
underli
diseas
particular
sever
respiratori
cardiovascular
diseas
transplant
recipi
although
viru
identifi
lung
tissu
prior
studi
two
fatal
case
cov
pneumonia
report
viru
detect
nasopharyng
aspir
patient
lymphopenia
suffer
diabet
mellitu
patient
year
old
gastric
lymphoma
year
old
prostat
carcinoma
patient
receiv
lymphodeplet
condit
regimen
autolog
hsct
result
prolong
b
cell
lymphopenia
sever
immunocompromis
hsct
immunosuppress
therapi
use
treat
possibl
lupu
pneumon
although
influenza
suspect
caus
patient
pneumon
repeatedli
isol
nasopharyng
wash
bal
fluid
immunohistochemistri
lung
tissu
obtain
biopsi
autopsi
fail
show
influenza
viru
inhal
zanamivir
may
reduc
sensit
cultur
immunohistochemistri
would
expect
show
evid
influenza
infect
viru
signific
caus
diseas
patient
although
influenza
viru
infect
may
contributor
patient
symptom
earli
hsct
continu
progress
bronchopneumonia
antivir
influenza
along
failur
identifi
influenza
lower
respiratori
tract
clinic
sampl
initi
posit
bal
week
transplant
autopsi
strongli
suggest
influenza
caus
fatal
ill
highli
immunocompromis
patient
known
shed
influenza
upper
respiratori
tract
month
influenza
viru
bal
fluid
may
due
shed
viru
upper
respiratori
tract
anoth
possibl
diagnosi
patient
idiopath
pneumonia
syndrom
ip
present
diffus
lung
injuri
without
evid
infect
patient
intermedi
period
transplant
day
median
time
onset
ip
day
post
transplant
ip
typic
describ
allogen
hsct
level
immunosuppress
usual
profound
standard
autolog
hsct
report
frequenc
ip
rang
averag
cov
respiratori
virus
may
respons
case
ip
reliabl
mean
detect
employ
increas
arsen
diagnost
tool
detect
respiratori
virus
develop
includ
rapid
antigen
detect
monoclon
antibodi
test
cell
cultur
variou
nucleic
acid
amplif
techniqu
howev
detect
respiratori
virus
includ
cov
remain
challeng
protocol
use
identifi
cov
case
sever
signific
advantag
method
univers
viru
detect
tool
provid
sequenc
inform
pathogen
present
given
sampl
without
prior
inform
genom
unbias
detect
limit
close
nucleic
acid
test
techniqu
use
primer
subtract
techniqu
might
use
order
identifi
pathogen
requir
uninfect
otherwis
genet
ident
control
may
difficult
obtain
clinic
sampl
previous
show
detect
limit
sever
order
magnitud
sensit
gener
detect
techniqu
isol
nucleic
acid
purifi
nucleocapsid
protocol
like
detect
intact
infecti
particl
pcr
whole
sampl
larg
amount
contamin
cellular
nucleic
acid
viral
nucleic
acid
sequenc
highli
enrich
pcr
perform
may
especi
use
find
pathogen
readili
identifi
standard
method
nonetheless
result
screen
techniqu
like
must
independ
verifi
exemplifi
detect
sequenc
autopsi
specimen
first
report
knowledg
cov
detect
directli
lung
tissu
individu
fatal
pneumonia
although
may
cov
infect
like
contribut
patient
fatal
outcom
patient
shed
influenza
viru
respiratori
tract
sever
month
viru
thought
caus
pneumonia
much
hospit
cours
transplant
influenza
infect
consid
less
like
lupu
pneumon
consid
possibl
receiv
immunosuppress
therapi
may
exacerb
cov
infect
rule
possibl
transient
improv
observ
increas
immunosuppress
therapi
due
reduct
inflammatori
respons
cov
infect
case
illustr
import
obtain
appropri
specimen
patient
unexplain
pneumon
valu
unbias
approach
univers
viru
detect
assay
employ
identifi
caus
pulmonari
infiltr
hypoxemia
